



May 25, 2012

Company name: Dainippon Sumitomo Pharma Co., Ltd  
Representative: Masayo Tada, President  
(Securities Code: 4506, 1st Section of TSE and OSE)  
Contact: Atsuko Higuchi, Director Corporate Communication  
(Phone: +81-6-6203-1407)

Sunovion Pharmaceuticals settles dispute on BROVANA<sup>®</sup> patent litigation

Dainippon Sumitomo Pharma, Co., Ltd. (DSP, Headquarters: Osaka, Japan; President: Masayo Tada) announces that its indirect, wholly-owned U.S. subsidiary, Sunovion Pharmaceuticals Inc. has reached agreements with Mylan Specialty L.P. (formerly Dey Pharma, L.P. and Dey, L.P.), Mylan Pharmaceuticals Inc., and Mylan Inc. to settle ongoing patent infringement litigation related to Sunovion's BROVANA<sup>®</sup> product. The case is Dey L.P., et al. v. Sunovion Pharmaceuticals Inc., Civil Action No. 07-2353 (JGK) (S.D.N.Y.). The terms of the agreements are confidential.